Dichloroacetate (DCA) is an environmentally important xenobiotics, widely distributed in our biosphere. It is also employed as an investigational drug for treatment of congenital forms of lactic acidosis (CLA). The cardinal manifestations of chronic DCA exposure are reversible hepatotoxicity and peripheral neuropathy (PN) in humans and hepatic neoplasia and reversible neurotoxicity in rodents. The etiologies of these adverse effects are obscure as in the relevance of the toxicological findings in animals to human risk assessment. DCA is dehalogenated by a glutathione transferase that is identical to maleylacetoacetate isomerase (MAAI), a key enzyme in tyrosine catabolism. Inhibition of MAAI by DCA causes accumulation of certain tyrosine catabolites, such as maleylacetone (MA), and heme precursors, such as ((-aminolevulinate ((-ALA) that may be responsible for its toxicity. The principal objective of this competitive renewal application is to elucidate the molecular mechanisms of DCA toxicity in rodents and humans by addressing the following specific aims and hypotheses:
Specific Aim 1 : Quantify the changes in tyrosine and heme metabolism in the urine of humans following exposure to DCA alone or in combination with pharmacologic inhibition of tyrosine catabolism.
This aim tests the postulate that the chemical NTBC, which inhibits an early step in tyrosine catabolism, will prevent or mitigate the clinical toxicity of DCA.
Specific Aim 2 : Determine the mechanism of DCA neurotoxicity in peripheral nerves of dosed humans undergoing treatment with DCA. These studies test the hypotheses 1) that the PN from DCA exposure is primarily due to selected disruption of neuronal cell metabolism, as a result of a direct effect of DCA and from accumulation of catabolites and (-ALA, and 2) that inhibition of this latter effect by NTBC mitigates neurologic damage.
Specific Aim 3 : Determine the mechanism of DCA neurotoxicity in peripheral nerves of dosed rats and in cultures of neuronal cells from rodents.
This aim will address the postulate that DCA induces neuropathology in rats by the same basic mechanisms as occurs in humans. It will also test the hypothesis that susceptibility to DCA PN is age-dependent, being increased in young animals in whom myelination of peripheral nerves is an active, ongoing process. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES007355-10
Application #
7077793
Study Section
Alcohol and Toxicology Subcommittee 4 (ALTX)
Program Officer
Thompson, Claudia L
Project Start
1995-04-01
Project End
2009-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
10
Fiscal Year
2006
Total Cost
$570,056
Indirect Cost
Name
University of Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Mangal, Naveen; James, Margaret O; Stacpoole, Peter W et al. (2018) Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children. J Clin Pharmacol 58:212-220
Shroads, A L; Coats, B S; McDonough, C W et al. (2015) Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children. J Clin Pharmacol 55:50-5
Langaee, Taimour Y; Zhong, Guo; Li, Wenjun et al. (2015) The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression. Pharmacogenet Genomics 25:239-45
Li, Wenjun; Gu, Yuan; James, Margaret O et al. (2012) Prenatal and postnatal expression of glutathione transferase ? 1 in human liver and the roles of haplotype and subject age in determining activity with dichloroacetate. Drug Metab Dispos 40:232-9
Shroads, Albert L; Langaee, Taimour; Coats, Bonnie S et al. (2012) Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol 52:837-49
Landgraf, Rachelle R; Garrett, Timothy J; Conaway, Maria C Prieto et al. (2011) Considerations for quantification of lipids in nerve tissue using matrix-assisted laser desorption/ionization mass spectrometric imaging. Rapid Commun Mass Spectrom 25:3178-84
Stacpoole, Peter W (2011) The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither? Environ Health Perspect 119:155-8
Garrett, Timothy J; Merves, Matthew; Yost, Richard A (2011) Characterization of protonated phospholipids as fragile ions in quadrupole ion trap mass spectrometry. Int J Mass Spectrom 308:299-306
Li, Wenjun; James, Margaret O; McKenzie, Sarah C et al. (2011) Mitochondrion as a novel site of dichloroacetate biotransformation by glutathione transferase zeta 1. J Pharmacol Exp Ther 336:87-94
Garrett, Timothy J; Yost, Richard A (2010) Tandem mass spectrometric methods for phospholipid analysis from brain tissue. Methods Mol Biol 656:209-30

Showing the most recent 10 out of 42 publications